The Peptide Landscape Is Shifting: What Secretary Kennedy's Joe Rogan Interview Could Mean for the Compounding Industry Frier Levitt FDA Peptide Regulation May Shift: What RFK Jr.'s Announcement Means for Compounding Is BPC 157 Banned? Oral vs. Injectable Forms Explained FDA Peptide Update: Category 2 Removals Explained FDA to Remove 12 Popular Peptides from the Category 2 Do Not Compound List Frier Levitt FDA Peptide Update 2026: Removal from Do Not Compound List and What It Means for Pharmacies FDA has removed certain bulk drug substances that were placed on the category two list and has announced it will consult the Pharmacy Compounding Advisory Committee (PCAC) for potential future inclusion of FDA takes first step in possible reversal of ban on some peptides The Washington Post